Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund
This article was originally published in The Pink Sheet Daily
Industry association warns of Cancer Drugs Fund's potential to worsen regional variations in access to cancer treatments.
You may also be interested in...
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.